<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866346</url>
  </required_header>
  <id_info>
    <org_study_id>2003-0564</org_study_id>
    <secondary_id>NCI-2012-01651</secondary_id>
    <nct_id>NCT00866346</nct_id>
  </id_info>
  <brief_title>PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation</brief_title>
  <official_title>A Phase I Study of PR1-Specific Cytotoxic T-Lymphocyte Infusion for Patients With Recurrent CML After Allogeneic Hematopoietic Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To determine the maximally tolerated dose of donor PR1-specific cytotoxic T-lymphocytes&#xD;
      (PR1-CTL) as treatment for relapsed or persistent chronic myelogenous leukemia (CML) after&#xD;
      allogeneic hematopoietic transplantation from an HLA-matched related or unrelated donor.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To evaluate the immunological response following PR1-CTL treatment&#xD;
&#xD;
        2. To evaluate the clinical efficacy by determining clinical, cytogenetic and molecular&#xD;
           response rates within 6 months&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before treatment starts, you will have a complete physical exam, including blood (about 2&#xD;
      tablespoons) tests. You will have a chest x-ray and bone marrow will be collected. To collect&#xD;
      a bone marrow sample, an area of the hip or chest bone is numbed with anesthetic and a small&#xD;
      amount of bone marrow is withdrawn through a large needle. Women who are able to have&#xD;
      children must have a negative blood pregnancy test.&#xD;
&#xD;
      You will be treated with donor immune cells (T lymphocytes) that will specifically target&#xD;
      certain leukemia cells in your body. Each participant will receive two doses of donor cells,&#xD;
      60 days apart. The second dose will be given 60 days after the first dose, at a higher dose&#xD;
      level, as long as no serious side effects occur after the first dose and there is still&#xD;
      disease present. Four dose levels of PR1-specific T lymphocytes will be considered. Up to 30&#xD;
      patients will be treated in cohorts of 3, starting at the lowest dose level, and not skipping&#xD;
      an untried dose level when escalating. The trial will be stopped early if the lowest dose&#xD;
      level is found to be unacceptably toxic.&#xD;
&#xD;
      These cells will be given on an outpatient basis. After each donor cell infusions, you will&#xD;
      be followed once a week in the outpatient clinic for at least 1 month and then every 3 months&#xD;
      for at least one year. You will have routine blood (about 2 tablespoons) and urine tests at&#xD;
      these visits. Participants experiencing side effects from their leukemia or leukemia&#xD;
      treatment may need to be hospitalized earlier.&#xD;
&#xD;
      You will also receive several other medications to help decrease the risk of infections while&#xD;
      your immune system is weak. These include preventative antibiotics, antiviral drugs, and&#xD;
      antifungal drugs.&#xD;
&#xD;
      Bone marrow samples will be taken before the second cell infusion, and then 8 weeks, 12&#xD;
      weeks, 6 months and 1 year after the second cell infusion.&#xD;
&#xD;
      This is an investigational study. A total of up to 30 patients will be take part in this&#xD;
      study. All will be enrolled at UTMDACC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study failed to accrue any patients due to regulatory issues with PR1 vaccine and T cell&#xD;
    production.&#xD;
  </why_stopped>
  <start_date>March 2008</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximally tolerated dose of donor PR1-specific cytotoxic T-lymphocytes (PR1-CTL)</measure>
    <time_frame>Continuous reassessment, infusion day 0 and second infusion day 60+/- 7</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>PR1-CTL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.&#xD;
Starting infusion dose 1 x 106 nucleated cells/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PR1-primed lymphocyte (PR1-CTL) Infusion</intervention_name>
    <description>Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.&#xD;
Starting infusion dose 1 x 106 nucleated cells/kg.</description>
    <arm_group_label>PR1-CTL</arm_group_label>
    <other_name>AHT</other_name>
    <other_name>Allogenic Hemotopoietic Transplantation</other_name>
    <other_name>PR1-CTL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with chronic myelogenous leukemia (CML) who have previously undergone&#xD;
             allogeneic hematopoietic transplantation and have evidence of disease, as defined by&#xD;
             a,b or c (a) &gt;5% Philadelphia chromosome positive cells on cytogenetic studies &gt;/= 3&#xD;
             months post-transplant&#xD;
&#xD;
          2. (b) For patients in cytogenetic remission post-transplant, molecular evidence of&#xD;
             disease at any time, defined as recurrence of quantitative PCR positivity for bcr-abl&#xD;
             after achieving a molecular remission confirmed by 2 assays, 3 months apart or sooner&#xD;
             if clinically indicated; OR a &gt;10-fold increase in the relative expression of&#xD;
             bcr-abl/abl detected and confirmed by a minimum of 2 consecutive PCR analysis, 3&#xD;
             months apart or sooner&#xD;
&#xD;
          3. (c) Molecular evidence of persistent disease on Real time PCR (bcr-abl/ abl x 100 of&#xD;
             0.05 and not declining) &gt;3 months post-transplantation after treatment with imatinib&#xD;
             mesylate.&#xD;
&#xD;
          4. Patients must have an HLA compatible related or unrelated donor capable of donating&#xD;
             peripheral blood stem cells using apheresis techniques. This must be the same donor&#xD;
             used for the original allogeneic hematopoetic transplantation. Patient must be HLA-A2&#xD;
             positive&#xD;
&#xD;
          5. ECOG performance status &lt; or = 2&#xD;
&#xD;
          6. Serum bilirubin &lt; or = 2 mg/dl&#xD;
&#xD;
          7. Serum transaminases &lt; 4 x normal&#xD;
&#xD;
          8. Serum creatinine &lt; or = 2 mg/dl&#xD;
&#xD;
          9. No active uncontrolled infection&#xD;
&#xD;
         10. HIV negative&#xD;
&#xD;
         11. No acute and/or chronic GVHD requiring systemic steroid therapy&#xD;
&#xD;
         12. Patient is not pregnant or breast feeding.&#xD;
&#xD;
         13. Signed informed consent&#xD;
&#xD;
         14. Patients must be off all immunosuppressive medications for at least 2 weeks prior to&#xD;
             study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muzaffar H. Qazilbash, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard E. Champlin, MD, BS</last_name>
    <role>Study Chair</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 18, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Myelogenous Leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Allogeneic Hematopoietic Transplantation</keyword>
  <keyword>Bone Marrow Transplant</keyword>
  <keyword>PR1-Specific Cytotoxic T-Lymphocyte Infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

